Semaglutide Weekly Injection Adherence: Real-World Patterns in T2D
Medication adherence analysis for semaglutide once-weekly injection in T2D patients reveals real-world compliance patterns, predictors of adherence, and discontinuation reasons.
Quick Facts
What This Study Found
Medication adherence analysis for semaglutide once-weekly injection in T2D patients reveals real-world compliance patterns, predictors of adherence, and discontinuation reasons.
Key Numbers
Cross-sectional study of semaglutide users at an outpatient pharmacy in Tabuk, Saudi Arabia, measuring first-year discontinuation and adherence.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Medication adherence analysis for semaglutide once-weekly injection in T2D patients reveals real-wor
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Medication Adherence to Semaglutide Once-Weekly Injection Among Type-2 Diabetes Patients in Tabuk, Saudi Arabia - A Cross-Sectional Study.
- Published In:
- Patient preference and adherence, 19, 2535-2551 (2025)
- Authors:
- Amirthalingam, Palanisamy(3), Alatawi, Olayan Salamah, Hamdan, Ahmed Mohsen Elsaid, Aljabri, Ahmed, Alqifari, Saleh, Alshareef, Hanan, Hakami, Faris Ahmed M, Albalawi, Nader Salem, A Albrahimi, Hazem Moufeed, Mubark Alanazi, Sultan Mohammed, Alatawi, Ahmed Mutair, Albalwi, Abdullah Abdalziz S, Ali, Mostafa A Sayed
- Database ID:
- RPEP-09930
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Medication adherence analysis for semaglutide once-weekly injection in T2D patients reveals real-world compliance patterns, predictors of adherence, and discontinuation reasons.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09930APA
Amirthalingam, Palanisamy; Alatawi, Olayan Salamah; Hamdan, Ahmed Mohsen Elsaid; Aljabri, Ahmed; Alqifari, Saleh; Alshareef, Hanan; Hakami, Faris Ahmed M; Albalawi, Nader Salem; A Albrahimi, Hazem Moufeed; Mubark Alanazi, Sultan Mohammed; Alatawi, Ahmed Mutair; Albalwi, Abdullah Abdalziz S; Ali, Mostafa A Sayed. (2025). Medication Adherence to Semaglutide Once-Weekly Injection Among Type-2 Diabetes Patients in Tabuk, Saudi Arabia - A Cross-Sectional Study.. Patient preference and adherence, 19, 2535-2551. https://doi.org/10.2147/PPA.S534534
MLA
Amirthalingam, Palanisamy, et al. "Medication Adherence to Semaglutide Once-Weekly Injection Among Type-2 Diabetes Patients in Tabuk, Saudi Arabia - A Cross-Sectional Study.." Patient preference and adherence, 2025. https://doi.org/10.2147/PPA.S534534
RethinkPeptides
RethinkPeptides Research Database. "Medication Adherence to Semaglutide Once-Weekly Injection Am..." RPEP-09930. Retrieved from https://rethinkpeptides.com/research/amirthalingam-2025-medication-adherence-to-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.